Earnings summaries and quarterly performance for SPRUCE BIOSCIENCES.
Executive leadership at SPRUCE BIOSCIENCES.
Board of directors at SPRUCE BIOSCIENCES.
Research analysts covering SPRUCE BIOSCIENCES.
Recent press releases and 8-K filings for SPRB.
Spruce Biosciences Presents Positive Long-Term Data for TA-ERT in MPS IIIB
SPRB
New Projects/Investments
- On February 5, 2026, Spruce Biosciences, Inc. announced positive long-term data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in patients with Sanfilippo Syndrome Type B (MPS IIIB) at the 22nd Annual WORLDSymposium™.
- The data demonstrated that TA-ERT resulted in a rapid and durable reduction of heparan sulfate and preserved cognitive and non-cognitive outcomes, including communication and motor skills, over a six-year period compared to natural history patients.
- The treatment's safety profile was consistent with intracerebroventricular administration, with approximately 6,000 doses administered to 22 patients over six years.
- This data highlights TA-ERT's potential as the first disease-modifying treatment option for MPS IIIB, a fatal condition with no approved therapies, and supports advancing the program towards a biologics license application submission and potential U.S. FDA approval.
1 day ago
Spruce Biosciences Secures Growth Capital from Avenue Capital
SPRB
Debt Issuance
New Projects/Investments
Guidance Update
- Spruce Biosciences entered into a loan facility with Avenue Capital on January 7, 2026, for up to $50 million in growth capital.
- An initial tranche of $15 million is expected to be funded around January 9, 2026, which is anticipated to extend the company's cash runway into 2027.
- The remaining $35 million is subject to the achievement of key regulatory and commercial milestones related to the development and planned launch of tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB).
- The loan facility has a 42-month term with a maturity date of July 1, 2029, and bears interest at an annual rate of at least 12.25%.
- As of December 31, 2025, Spruce Biosciences reported preliminary cash and cash equivalents of approximately $48.9 million.
Jan 8, 2026, 1:05 PM
Spruce Biosciences Secures Up to $50 Million in Growth Capital
SPRB
Debt Issuance
New Projects/Investments
Guidance Update
- On January 7, 2026, Spruce Biosciences entered into a loan facility with Avenue Capital for up to $50 million in growth capital.
- The facility includes an initial tranche of $15 million, expected to be funded around January 9, 2026, with the remaining $35 million contingent on regulatory and commercial milestones for TA-ERT.
- This funding is anticipated to extend the company's cash runway into 2027.
- As of December 31, 2025, Spruce Biosciences reported approximately $48.9 million in cash and cash equivalents.
Jan 8, 2026, 1:00 PM
Spruce Biosciences, Inc. Announces Director Resignation and Stock Option Repricing
SPRB
Board Change
Executive Compensation
- Tiba Aynechi, Ph.D. resigned from Spruce Biosciences, Inc.'s board of directors and as Chair of the Compensation Committee, effective December 11, 2025.
- On December 11, 2025, the Board approved a stock option repricing, reducing the exercise price of certain outstanding options to $104.13 per share.
- This repricing impacts 30,174 shares underlying options held by employees and directors, including the CEO and CFO, which previously had exercise prices ranging from $108.00 to $1,506.00 per share.
- A retention period is required for the reduced exercise price to apply, with the repricing designed to retain and motivate option holders without significant stock dilution or additional cash compensation.
Dec 12, 2025, 9:03 PM
Spruce Biosciences Reports Q3 2025 Results, Secures Financing, and Receives Breakthrough Therapy Designation
SPRB
Earnings
New Projects/Investments
Delisting/Listing Issues
- Spruce Biosciences reported a net loss of $8.2 million for the third quarter ended September 30, 2025, with cash and cash equivalents of $10.7 million as of that date.
- The company completed a $50.0 million private placement financing in October 2025, which, combined with existing cash, is expected to fund operations into the fourth quarter of 2026.
- The U.S. FDA granted Breakthrough Therapy Designation for its Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB) in October 2025, with a Biologics License Application submission on track for the first quarter of 2026.
Nov 10, 2025, 9:07 PM
Spruce Biosciences Reports Q3 2025 Results and Key Corporate Updates
SPRB
Earnings
New Projects/Investments
Guidance Update
- Spruce Biosciences received Breakthrough Therapy Designation from the U.S. FDA for its Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB) in October 2025.
- The company completed a $50.0 million private placement financing in October 2025, which, combined with existing cash, is expected to fund operations into the fourth quarter of 2026.
- A Biologics License Application (BLA) submission for TA-ERT for MPS IIIB is anticipated in the first quarter of 2026.
- For the third quarter ended September 30, 2025, Spruce Biosciences reported a net loss of $8.2 million and total operating expenses of $8.2 million.
Nov 10, 2025, 9:05 PM
Spruce Biosciences Announces $50 Million Private Placement
SPRB
New Projects/Investments
- Spruce Biosciences, Inc. entered into a Securities Purchase Agreement on October 7, 2025, for a private placement of common stock and pre-funded warrants.
- The company will sell 502,181 shares of common stock at $68.00 per share and pre-funded warrants to purchase up to 233,144 shares of common stock at $67.99 per warrant.
- The private placement is expected to close on or about October 9, 2025, with anticipated gross proceeds of approximately $50.0 million.
- The company intends to use the proceeds to advance tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), targeting a biologics license application submission in Q1 2026 and potential U.S. commercial launch in late 2026.
Oct 8, 2025, 8:07 PM
Spruce Biosciences Announces Private Placement Financing
SPRB
New Projects/Investments
- Spruce Biosciences has entered into a definitive securities purchase agreement for a private placement, which is expected to generate gross proceeds of approximately $50.0 million.
- The financing is intended to advance tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) through a biologics license application (BLA) submission in the first quarter of 2026 and a potential U.S. commercial launch in late 2026.
- Investors will purchase approximately 502,181 shares of common stock at $68.00 per share, and pre-funded warrants for up to 233,144 shares of common stock at $67.99 per warrant.
- The private placement is expected to close on or about October 9, 2025.
Oct 8, 2025, 12:00 PM
Spruce Biosciences Gains FDA Breakthrough Therapy Designation for Sanfilippo Syndrome Drug
SPRB
New Projects/Investments
- Spruce Biosciences received Breakthrough Therapy Designation from the FDA for its enzyme replacement therapy, tralesinidase alfa (TA-ERT), targeting Sanfilippo Syndrome Type B. This designation is supported by clinical data showing rapid and durable effects and the FDA confirmed the biomarker could serve as a surrogate endpoint for potential accelerated approval.
- The company plans to submit its Biologics License Application for TA-ERT in early 2026.
- Despite facing financial challenges, including negative profit margins and risk of bankruptcy, Spruce Biosciences maintains strong liquidity with a current ratio and quick ratio both at 2.6.
- Following the announcement, Spruce's stock surged significantly, reflecting investor optimism about the therapy's potential.
Oct 6, 2025, 12:29 PM
Spruce Biosciences Receives FDA Breakthrough Therapy Designation for TA-ERT
SPRB
Product Launch
New Projects/Investments
- Spruce Biosciences received U.S. FDA Breakthrough Therapy Designation (BTD) for its tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB).
- The BTD was supported by clinical data demonstrating normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), which the FDA confirmed is a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval.
- The company remains on track to submit the Biologics License Application (BLA) for TA-ERT for MPS IIIB in the first quarter of 2026.
- TA-ERT is highlighted as a potentially transformative clinical impact as the first disease-modifying therapy for MPS IIIB, a fatal genetic disease with no current FDA-approved treatments.
Oct 6, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more